Dasiglucagon for treating severe hypoglycemia in patients with diabetes

References

• Amiel SA, Aschner P, and Childs B, International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7(5):385–396. .
   Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society. Diabetes Care. 2013;36(5):1384–1395.
   Google Scholar
• Muneer MH. Hypoglycaemia. Adv Exp Med Biol. 2021;1307:43–69.
   Google Scholar
• Balijepalli C, Druyts E, Siliman G, et al. Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes. Clin Epidemiol. 2017;9:291–296.
   Google Scholar
• Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. Jama. 2017;317(4):371–378.
   Google Scholar
• Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018;361:k1310.
   Google Scholar
• Cryer PE, Longo DL. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369(4):362–372.
   Google Scholar
• Beato-Víbora PI, Arroyo-Díez FJ. New uses and formulations of glucagon for hypoglycaemia. Drugs Context. 2019;8:212599.
   Google Scholar
• Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes. 2011;4:337–346.
   Google Scholar
• Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol. 2010;4(6):1357–1367.
   Google Scholar
• U.S. Food and Drug Administration. ZEGALOGUE (dasiglucagon) injection, for subcutaneous use. cited 2021 Apr 15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf
   Google Scholar
• Abraham MB, Jones TW, Naranjo D, et al. ISPAD clinical practice consensus guidelines 2018: assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):178–192.
   Google Scholar
• Authier F, Desbuquois B. Glucagon receptors. Cell Mol Life Sci. 2008;65(12):1880–1899.
   Google Scholar
• Steiner SS, Li M, Hauser R, et al. Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol. 2010;4(6):1332–1337.
   Google Scholar
• Ghodke S, Nielsen SB, Christiansen G, et al. Mapping out the multistage fibrillation of glucagon. FEBS J. 2012;279(5):752–765. 08465.x.
   Google Scholar
• Pohl R, Li M, Krasner A, et al. Development of stable liquid glucagon formulations for use in artificial pancreas. J Diabetes Sci Technol. 2015;9(1):8–16.
   Google Scholar
• U.S. Food and Drug Administration. BAQSIMI (glucagon) nasal powder. cited 2021 Jul 24. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf
   Google Scholar
• Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264–270.
   Google Scholar
• Peters TM, Haidar A. Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems. Diabet Med. 2018;35(4):450–459.
   Google Scholar
• GJ T Jr. The physiology of glucagon. J Diabetes Sci Technol. 2010;4(6):1338–1344.
   Google Scholar
• Taleb N, Emami A, Suppere C, et al. Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial. Diabetologia. 2016;59(12):2561–2571.
   Google Scholar
• Castle JR, Elander M. Long-Term Safety and Tolerability of Dasiglucagon, a Stable-in-Solution Glucagon Analogue. Diabetes Technol Ther. 2019;21(2):94–96.
   Google Scholar
• U.S. Food and Drug Administration. Clinical pharmacology review(s). cited April 15. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000ClinPharmR.pdf
   Google Scholar
• U.S. Food and Drug Administration. Non-clinical review(s). cited 2021 Jul 24. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000PharmR.pdf
   Google Scholar
• Li S, Hu Y, Tan X, et al. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes. Expert Opin Pharmacother. 2020;21(11):1311–1318.
   Google Scholar
• Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531–537.
   Google Scholar
• Hövelmann U, Olsen MB, Mouritzen U, et al. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Diabetes Obes Metab. 2019;21(3):601–610.
   Google Scholar
• U.S. Food and Drug Administration. Clinical review(s); 2021. cited 2021 Apr 15. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000MedR.pdf.
   Google Scholar
• ClinicalTrials.gov.trial to confirm the clinical efficacy and safety of dasiglucagon in the treatment of hypoglycemia in subjects with T1DM. cited 2021 Apr 15. https://www.clinicaltrials.gov/ct2/show/NCT03688711?term=NCT03688711&draw=2&rank=1
   Google Scholar
• Pieber TR, Aronson R, Hövelmann U, et al. Dasiglucagon: a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia results of phase 3 randomized double-blind clinical trial. Diabetes Care. 2021;dc202995. DOI:10.2337/DC20-2995.
   Google Scholar
• Battelino T, Tehranchi R, Bailey T, et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial. Pediatr Diabetes. 2021;13220. DOI:10.1111/pedi.13220.
   Google Scholar
• American Diabetes Association. Glycemic Targets: standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1): S66–S76.
   Google Scholar
• Iqbal A, Heller S. Managing hypoglycaemia. Best Pract Res Clin Endocrinol Metab. 2016;30(3):413–430.
   Google Scholar
• Roženková K, Güemes M, Shah P, et al. The diagnosis and management of hyperinsulinaemic hypoglycaemia. J Clin Res Pediatr Endocrinol. 2015;7(2):86–97.
   Google Scholar
• Harris GDA, Sulway W, Wilkinson M. Glucagon administration - underevaluated and underthought. Pract Diabetes Int. 2001;18(1):22–25
   Google Scholar
• Janah L, Kjeldsen S, Galsgaard KD, et al. Glucagon receptor signaling and glucagon resistance. Int J Mol Sci. 2019;20(13):3314.
   Google Scholar
• Kleinert M, Sachs S, Habegger KM, et al. Glucagon regulation of energy expenditure. Int J Mol Sci. 2019;20(21):5407.
   Google Scholar
• Hawkes CP, De Leon DD, Rickels MR. Novel preparations of glucagon for the prevention and treatment of hypoglycemia. Curr Diab Rep. 2019;19(10):97.
   Google Scholar